Multipotent mesenchymal stromal cells: optimization and comparison of five cationic polymer-based gene delivery methods

被引:49
作者
Gheisari, Y. [1 ,2 ]
Soleimani, M. [3 ]
Azadmanesh, K. [1 ,4 ]
Zeinali, S. [1 ]
机构
[1] Pasteur Inst Iran, Dept Mol Med, Tehran, Iran
[2] Isfahan Univ Med Sci, Dept Genet & Mol Biol, Esfahan, Iran
[3] Tarbiat Modares Univ, Dept Hematol, Tehran, Iran
[4] Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran
关键词
flow cytometry; mesenchymal stromal cells; transfection;
D O I
10.1080/14653240802474307
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background Multipotent mesenchymal stromal cells (MSC) are promising candidates in the field of regenerative medicine and in several studies have been genetically modified to bring a new property to or enhance an existing one in these cells. Furthermore, MSC have been used as gene delivery vehicles. The success of these experiments depends on selecting an appropriate method for gene delivery to the cells. Methods MSC were isolated from rat bone marrow; their authenticity was checked by differentiation experiments as well as staining for cell-surface markers. A systematic approach was used to optimize five cationic polymer-based gene delivery methods (Lipofectamin2000, Effecten, Superfect, Polyfect and FuGENE HD). The transfection yield and cell viability of each method was measured after 48 h in three to six separate experiments with nine to 12 different ratios and amounts of DNA/transfection reagent. Results The isolated MSC were successfully differentiated to osteoblasts, adipocytes and chondroblasts. They were positive for rat CD90 and CD73 and negative for CD31, CD45, CD11b and VEGFR2 markers. The average transfection rates with optimum conditions were 5.18 +/- 2.72 (FuGENE HD), 8.72 +/- 4.52 (Effecten), 9.59 +/- 3.12 (Superfect), 16.29 +/- 7.44 (Polyfect) and 19.60 +/- 3.12 (Lipofectamine 2000). The toxicity was below 20% for all reagents. Discussion Moderate levels of transfection and acceptable cell viability could be achieved using Lipofectamine 2000 and Polyfect in optimized conditions. The results could be improved by gating and sorting live cells using a simple FSC-SSC gating.
引用
收藏
页码:815 / 823
页数:9
相关论文
共 22 条
  • [1] Human mesenchymal stem cells modulate allogeneic immune cell responses
    Aggarwal, S
    Pittenger, MF
    [J]. BLOOD, 2005, 105 (04) : 1815 - 1822
  • [2] Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
    Dominici, M.
    Le Blanc, K.
    Mueller, I.
    Slaper-Cortenbach, I.
    Marini, F. C.
    Krause, D. S.
    Deans, R. J.
    Keating, A.
    Prockop, D. J.
    Horwitz, E. M.
    [J]. CYTOTHERAPY, 2006, 8 (04) : 315 - 317
  • [3] Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor
    Duan, HF
    Wu, CT
    Wu, DL
    Lu, Y
    Liu, HJ
    Ha, XQ
    Zhang, QW
    Wang, H
    Jia, XX
    Wang, LS
    [J]. MOLECULAR THERAPY, 2003, 8 (03) : 467 - 474
  • [4] Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells
    Hoelters, J
    Ciccarella, M
    Drechsel, M
    Geissler, C
    Gülkan, H
    Böcker, W
    Schieker, M
    Jochum, M
    Neth, P
    [J]. JOURNAL OF GENE MEDICINE, 2005, 7 (06) : 718 - 728
  • [5] Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: Benefit of a novel nonviral vector, cationized dextran
    Jo, Jun-Ichiro
    Nagaya, Noritoshi
    Miyahara, Yoshinori
    Kataoka, Masaharu
    Harada-Shiba, Mariko
    Kangawa, Kenji
    Tabata, Yasuhiko
    [J]. TISSUE ENGINEERING, 2007, 13 (02): : 313 - 322
  • [6] Kicic A, 2003, J NEUROSCI, V23, P7742
  • [7] Lipoplex formulation of superior efficacy exhibits high surface activity and fusogenicity, and readily releases DNA
    Koynova, Rumiana
    Tarahovsky, Yury S.
    Wang, Li
    MacDonald, Robert C.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (02): : 375 - 386
  • [8] Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes
    Kunter, Uta
    Rong, Song
    Boor, Peter
    Eitner, Frank
    Mueller-Newen, Gerhard
    Djuric, Zivka
    van Roeyen, Claudia R.
    Konieczny, Andrzej
    Ostendorf, Tammo
    Villa, Luigi
    Milovanceva-Popovska, Maja
    Kerjaschki, Dontscho
    Floege, Juergen
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (06): : 1754 - 1764
  • [9] BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model
    Kurozumi, K
    Nakamura, K
    Tamiya, T
    Kawano, Y
    Kobune, M
    Hirai, S
    Uchida, H
    Sasaki, K
    Ito, Y
    Kato, K
    Honmou, O
    Houkin, K
    Date, I
    Hamada, H
    [J]. MOLECULAR THERAPY, 2004, 9 (02) : 189 - 197
  • [10] Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Le Blanc, K
    Rasmusson, I
    Sundberg, B
    Götherström, C
    Hassan, M
    Uzunel, M
    Ringdén, O
    [J]. LANCET, 2004, 363 (9419) : 1439 - 1441